Payers Reveal Most Significant Factors Impacting Biosimilar Coverage Decisions
June 29th 2023It was found that cancer treatment, pediatric population, and coverage restriction of reference products were revealed as some of the strongest factors associated with biosimilar coverage decisions by US commercial health plans relative to reference products.
Multiple Infliximab Biosimilar Switches Appear Safe, Effective for Patients With IBD
April 20th 2023A retrospective study in Scotland found that multiple successive changes from originator infliximab to biosimilars seem to be safe and effective in patients with inflammatory bowel disease (IBD), irrespective of the number of switches.
Christine Baeder Discusses the Future of the Biosimilar Industry, Insulins
April 9th 2023Upon coming into her position as the new chair of the Association for Accessible Medicines (AAM), Christine Baeder discussed what she believes the future holds for biosimilars, good and bad, and the questions that still surround the insulin price cap.
Christine Baeder Discusses Generic Awareness and Challenges that Lie in Biosimilar in Generic Spaces
March 28th 2023Upon coming into her position as the new chair of the Association for Accessible Medicines (AAM) as well as chief operating officer for US generics and biosimilars at Teva Pharmaceuticals USA, Christine Baeder discusses her primary goals in this position, and the challenges that accompany them.
Favorable Equivalency Studies of Candidate Biosimilar AVT04 and Reference Ustekinumab
March 27th 2023Posters presented by Alvotech at 2023 American Academy of Dermatology (AAD) annual meeting showcased proven bioequivalence and therapeutic equivalence candidate biosimilar AVT04 and reference ustekinumab (Stelara).